It was in 2001 that the company started its operations. Registered as a biopharmaceutical company, AVEO has several product candidates that are in various phases of clinical studies. These medications are created based on their proprietary Human Response Platform. These products are intended to treat cachexia and for various vascular endothelial growth factors. These novelty therapeutics provide targeted therapeutics for patients with cancer and other related diseases.
The company was created as GenPath Pharmaceuticals. In 2005, the company adopted its current brand name. Headquartered in Cambridge, Massachusetts, the company has strategic partnerships with several other research and pharmaceutical companies. Currently, the company employs the expertise of 57 experts in the field of oncology and drug development.